We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




POC Chlamydia and Gonorrhea Combo Test Gives Results in 30 Minutes

By LabMedica International staff writers
Posted on 16 Aug 2023

Despite the existence of highly sensitive and specific laboratory-based molecular diagnostic tools, the U. More...

S. has seen a steady rise in Chlamydia trachomatis and Neisseria gonorrhea (CT/NG) infections in recent years. Surprisingly, about 50% of eligible women don't get screened for these STIs according to the guidelines laid down by the Centers for Disease Control and Prevention (CDC). The traditional testing processes for CT/NG often lead to less-than-ideal outcomes. Patients sometimes receive potentially inappropriate treatments, may not always comply with prescribed treatments, and might face a treatment delay, having to wait nearly 10 days for lab results. By introducing rapid point-of-care (POC) tests, the time between diagnosing and treating these STIs can be reduced, subsequently lowering the chances of further transmission and related complications.

The binx io Platform from binx health (Boston, MA, USA) is the first FDA-approved, CLIA-Waived CT/NG molecular test suitable for both genders, enabling on-the-spot diagnosis and treatment. This platform can deliver results equivalent to those of lab-based tests in just about 30 minutes, in contrast to the days or weeks often required by traditional methods. The binx io platform combines the binx health io CT/NG Assay, an automated, fast, and qualitative test, and the binx health io Instrument, to detect CT/NG DNA using the polymerase chain reaction (PCR) process. By combining ultra-rapid PCR with unique electrochemical detection, the platform ensures results that are as reliable as those available from central labs. The desktop-sized device is user-friendly, allowing operation by staff who might not have formal lab training, even in CLIA-Waived environments.

The binx health io CT/NG Assay is a versatile test; it can use swabs from females (either clinician-collected or self-collected in a clinic) or male urine samples to diagnose CT/NG infections. A recent study compared the workflow of the io CT/NG Assay to traditional lab-based tests. Findings revealed that the time clinic staff spent operating the binx io CT/NG test wasn't statistically different from the time spent preparing samples for a lab. Essentially, while the tasks might differ, the total time spent remains similar. The major advantage, however, is that the binx io delivers actionable results in roughly 30 minutes. This means it can integrate smoothly into a typical patient visit, shifting the focus from sending out samples for lab testing to immediate in-clinic testing without creating an extra workload for the clinic staff.

“The data further support that the binx io provided test results reasonable for a single patient-visit compared to 16 hours for the laboratory-based results,” said Jeffrey Luber, Chief Executive Officer of binx health. “This time-to-result is extremely important for providing clinically actionable information and improving the quality of a patient’s care.”

Related Links:
binx health 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
PBC Assay
Primary Biliary Cholangitis Assays
New
UHF RFID Tag & Inlay
AD-327 U9 ETSI Pure 95
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.